Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say

Stryker (SYK) reported robust Q2 2025 results, with revenue up 11.1% year-over-year to $6.02 billion and EPS at $3.13, both exceeding consensus estimates by 1.09% and 2.29% respectively. Key drivers included the MedSurg and Neurotechnology segment, which grew 21% to $3.77 billion and surpassed estimates, while the Orthopaedics segment declined 2.3% to $2.25 billion, missing analyst projections. Despite the overall beat, SYK shares have returned -0.7% over the past month, underperforming the broader S&P 500.

Analysis

Stryker (SYK) delivered a solid Q2 2025 earnings beat, with revenue reaching $6.02 billion, an 11.1% year-over-year increase that surpassed consensus estimates by 1.09%. Similarly, EPS of $3.13 exceeded analyst expectations by 2.29%. However, this headline strength masks a significant performance divergence between its core business units. The MedSurg and Neurotechnology segment was the standout performer, growing 21% year-over-year to $3.77 billion and beating forecasts, driven by notable strength in Endoscopy (+17.1% YoY) and Trauma and Extremities (+15% YoY). In stark contrast, the Orthopaedics segment contracted by 2.3% to $2.25 billion, missing its consensus estimate of $2.29 billion. The weakness within Orthopaedics was primarily concentrated in its international business, which reported nearly flat growth (+0.2% YoY) and significantly missed analyst projections. Despite the overall earnings beat, the stock's recent -0.7% return over the past month, underperforming the S&P 500, suggests that investors are focusing on this segmental weakness.

Key Decisions for Investors

• Investors should weigh the robust, estimate-beating growth in the MedSurg and Neurotechnology division against the unexpected revenue miss and 2.3% year-over-year decline in the Orthopaedics segment.
• It is critical to monitor the performance of international Orthopaedics, as its significant underperformance was the primary drag on the segment and a key factor for the stock's muted reaction to the earnings beat.
• Given the stock's recent underperformance despite the top- and bottom-line beat, a neutral or hold-oriented stance may be prudent until there is more clarity on a potential turnaround in the Orthopaedics business.
• Consider that the strong growth in sub-segments like Trauma and Extremities (+15%) and Endoscopy (+17.1%) confirms pockets of high performance, but this is being offset by weakness elsewhere, creating a mixed forward-looking picture.